---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107617"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:57:10.374223+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma Q2 revenue $15.7M, neffy volume +180% QoQ, net loss $44.9M

## Summary
- Total revenue $15.7M, including $12.8M neffy U.S. net product revenue and $2.6M milestone from ALK.
- Net loss of $44.9M ($0.46/sh); SG&A $54.3M driven by DTC campaign; cash $240.1M.
- neffy weekly script volumes grew ~180% from Q1 end to Q2 end; 93% commercial coverage achieved.
- EUR neffy approved in UK and launched in Germany; $5M milestone triggered from ALK.
- Phase 2b urticaria trial initiated; topline data expected H1 2026.

## SEC filing metadata
- accession: 0000950170-25-107617
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000095017025107617/0000950170-25-107617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000095017025107617/spry-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107617
- JSON: https://secwatch.observer/filing/0000950170-25-107617.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.